Obstacles and Advances in Maternal Immunization During Pregnancy

Sponsored by Pfizer


Course Description

In this virtual session, we will review the immunology of how vaccines delivered to the pregnant parent during gestation create antibodies that cross the placenta. We will learn about the mechanism of action of pregnancy vaccines and how they support immunity in the newborn for the first months after birth. We will review current vaccines during pregnancy, why these are recommended and learn about new vaccines that are being explored for future distribution.
Learning Objectives

At the conclusion of this session, participants will be able to:
  1. List the vaccines that are currently recommended to be given during pregnancy
  2. Appreciate the rationale for administering each of the recommended vaccines during pregnancy during specific (and different) weeks of gestation
  3. Understand the mechanism for how vaccines given to pregnant women offer protection to their newborns
  4. Appreciate the important distinction between precautions and contraindications to administering vaccines during pregnancy
  5. Describe some of the known obstacles and offer several potential solutions to achieving optimal vaccination coverage among pregnant women

Speakers
Joseph Domachowske, MD FAAP, FIDSA, FPIDS


Speakers Bios
Dr. Joseph Domachowske (he/him) is Professor of Pediatrics and Professor of Microbiology and Immunology at Upstate Medical University in Syracuse, New York. There he serves as the Director of the Maternal-Child and Pediatric Global Health Program at the Institute for Global Health and Translational Science. His research is focused on broadening the understanding and reducing the morbidity of respiratory viral infections in newborns, infants and young children.

He has served as PI on more than 60 clinical trials, the majority of which have evaluated the safety and efficacy of new immunization candidates across vulnerable populations, including newborns, infants, young children and pregnant women. Currently, he and his experienced team of clinical research assistants are involved in clinical trials designed to evaluate novel investigational vaccines and passive immunoprophylaxis regimens for the prevention of RSV, congenital CMV, varicella, invasive meningococcal infection, and COVID19.

His career efforts to date have contributed to the FDA licensure and/or emergency use authorization of 18 new vaccines and have led to the publication of more than 175 scientific papers in high impact journals including the New England Journal of Medicine, the Lancet, Nature Communications, Pediatrics, Journal of Infectious Diseases, and Vaccine.

Course expiration: September 20, 2026